Close

IMGN Financial Facts

Loss from operations: -38.84M
Research and development support: 1.35M
See Full Income Statement

Inventory: 2.03M
Total shareholders' equity: -122.54M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 4/25/24 *Est. EPS Growth Rate +100.0% *Last Qtr.
Average EPS % Beat Rate +73.5% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS +51.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
1/27/11 Q211 -$0.21-$0.22 +$0.01$4.2M$4.07M N/A Details
4/28/11 Q311 -$0.22-$0.23 +$0.01$5.2M$4.19M N/A Details
8/3/11 Q411 -$0.23-$0.24 +$0.01N/A$4.41M N/A Details
10/27/11 Q112 -$0.26-$0.22 -$0.04$2.5M$5.61M N/A Details
1/27/12 Q212 -$0.17-$0.23 +$0.06$7.6M$5.43M N/A Details
4/27/12 Q312 -$0.24-$0.25 +$0.01$3.25M$4.24M N/A Details
8/3/12 Q412 -$0.29-$0.30 +$0.01$2.95M$3.26M N/A Details
10/26/12 Q113 -$0.30-$0.25 -$0.05$4.1M$4.1M N/A Details